The Department of Health and Human Services today announced that it will partner with the Department of Defense to fund the advanced development — including clinical trials and large-scale manufacturing — of a COVID-19 investigational vaccine from Sanofi and GlaxoSmithKline.

The investment is expected to yield 100 million fill-finished doses, meaning vaccine doses are packaged and ready to ship immediately if clinical trials are successful and the Food and Drug Administration authorizes its use.

Related News Articles

Headline
The Food and Drug Administration last week revoked its emergency use authorization for a SARS-CoV-2 antibody test made by Autobio Diagnostics Co. due to…
Headline
President Trump Saturday authorized the Federal Emergency Management Agency to use up to $44 billion in Stafford Act disaster relief funds to supplement…
Headline
The Health Resources and Services Administration expects in mid-August to distribute half of the $5 billion in Provider Relief Funds announced last month to…
Headline
In an op-ed published in Fierce Healthcare today, Robyn Begley, AHA’s chief nursing officer and CEO of the American Organization for Nursing Leadership, urged…
Chairperson's File
During the COVID-19 pandemic, hospitals remain cornerstones of their communities, as they’ve always been. They continue to serve and heal, provide jobs, food,…
Headline
Rural hospitals, already facing enormous challenges, quickly adapted when COVID-19 reached their communities. In this blog, John Supplitt, senior director…